We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Meconium Microbiome Can Help Predict Risk of Developing Allergies

By LabMedica International staff writers
Posted on 12 May 2021
Meconium, which is typically passed within the first day of life, is made up of a variety of materials ingested and excreted during development, ranging from skin cells, amniotic fluid and various molecules known as metabolites.

Microbiota maturation begins in earnest immediately after birth, when pioneering bacteria are introduced into the neonatal gut and form a niche capable of supporting successive colonizers that will comprise the infant microbiota. More...
Maturation of this microbial community continues through the first few years of life and occurs concomitantly with dramatic shifts in host immune function.

A team of scientists from the University of British Columbia (Vancouver, BC, Canada) analyzed meconium samples from 37 healthy control infants and 63 atopy infants enrolled in the CHILD Cohort Study (CHILD), a world-leading birth cohort study in maternal, newborn and child health studies. These samples were analyzed by Metabolon, Inc (Morrisville, NC, USA) for non-targeted metabolic profiling via their mView Global Metabolomics Profiling Platform using Ultrahigh Performance Liquid Chromatography-Tandem Mass Spectroscopy (UPLC-MS/MS).

The scientists discovered that the fewer different types of molecules a baby's meconium contained, the greater the child's risk of developing allergies by one year. They also found that a reduction in certain molecules was associated with changes to key bacterial groups. These bacteria groups play a critical role in the development and maturation of a vast ecosystem of gut microbes, known as the microbiota, which is a powerful player in health and disease. Using a machine-learning algorithm, the scientists combined meconium, microbe and clinical data to predict with a high degree of accuracy (76%), and more reliably than ever before, whether or not an infant would develop allergies by one year of age.

Stuart E. Turvey, MBBS, DPhil, FRCPC, a Professor of Pediatrics and the senior author of the study, said, “We know that children with allergies are at the highest risk of also developing asthma. Now we have an opportunity to identify at-risk infants who could benefit from early interventions before they even begin to show signs and symptoms of allergies or asthma later in life.” The study was published on April 29, 2021 in the journal Cell Reports Medicine.

Related Links:
University of British Columbia
Metabolon, Inc



Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.